References in periodicals archive ?
In addition, Gilead recorded product revenues of $1.4 million and $1.2 million from the sale of VISTIDE(R) (cidofovir injection) and DaunoXome(R) (daunorubicin citrate liposome injection), respectively, during the third quarter of 1999.